News coverage about Clearside Biomedical (NASDAQ:CLSD) has been trending somewhat positive this week, according to Accern. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Clearside Biomedical earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.7904885677138 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- Clearside Biomedical to Present at the 17th Annual Needham Healthcare Conference (finance.yahoo.com)
- Clearside BioMedical, Inc. (CLSD) stock jumped 26.11% versus to SMA-20 – The Stocks News (press release) (thestocksnews.com)
- Clearside Biomedical (CLSD) Rating Reiterated by Wedbush (americanbankingnews.com)
- Clearside BioMedical, Inc. (CLSD) crosses 57.03% over SMA-50 – The Stocks News (press release) (thestocksnews.com)
- Clearside Biomedical Inc (CLSD) Receives Consensus Recommendation of “Hold” from Brokerages (americanbankingnews.com)
Shares of CLSD stock traded up $0.53 during midday trading on Wednesday, hitting $12.38. The stock had a trading volume of 304,976 shares, compared to its average volume of 922,309. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.57 and a current ratio of 2.90. Clearside Biomedical has a 12-month low of $5.30 and a 12-month high of $15.06. The stock has a market capitalization of $381.36, a P/E ratio of -5.29 and a beta of -5.48.
CLSD has been the subject of a number of research reports. Zacks Investment Research raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Friday, December 8th. Wedbush reissued a “buy” rating on shares of Clearside Biomedical in a research note on Wednesday, February 7th. Needham & Company LLC increased their price target on Clearside Biomedical from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, March 6th. JMP Securities reissued an “outperform” rating and set a $25.00 price target on shares of Clearside Biomedical in a research note on Monday, March 5th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $18.00 price objective (up from $15.00) on shares of Clearside Biomedical in a research note on Tuesday, March 6th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $19.83.
WARNING: This story was posted by BBNS and is the sole property of of BBNS. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://baseballnewssource.com/2018/03/21/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-clearside-biomedical-clsd-share-price/2027438.html.
About Clearside Biomedical
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.